XML 33 R8.htm IDEA: XBRL DOCUMENT v3.22.2

Financial Instruments

6 Months Ended

Jun. 30, 2022

Financial Instruments

Financial Instruments

Note 3 – Financial Instruments

​

​ ​ ​ ​ ​ ​

Genmab’s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab’s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows:

​

​	​	​	​	​	​	​
​		June 30,		​	December 31,
​	​	2022		​	2021
Percent	​	​	​	​	​	​
​	​	​	​	​	​	​
USD		79	%	​	75	%
DKK	​	13	%	​	16	%
EUR	​	7	%	​	8	%
GBP		1	%	​	1	%
Total		100	%	​	100	%

​

​

As of June 30, 2022, 71% of Genmab’s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated by S&P, Moody’s or Fitch compared to 68% as of December 31, 2021.

​

The table below shows the fair value measurements by level for Genmab’s financial assets measured at fair value through profit or loss:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(DKK million)

​

June 30, 2022

​

December 31, 2021

Assets Measured at Fair Value

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total

​

​

​

​

​

​

​

​

​

​

​

​

​

Marketable securities

​

11,799

​

—

​

—

​

11,799

​

10,381

​

—

​

—

​

10,381

Other investments

​

150

​

—

​

51

​

201

​

344

​

—

​

27

​

371

​

Marketable Securities

All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab’s marketable securities (Level 1).

​

Other Investments

Other investments as of June 30, 2022 consist primarily of a DKK 138 million investment in common shares of CureVac, compared to DKK 318 million as of December 31, 2021. During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2022, the investment in Bolt was valued at DKK 12 million, compared to DKK 26 million as of December 31, 2021.

​

The investments in CureVac and Bolt are recorded at fair value through profit or loss. The fair value of Genmab’s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).

​

Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab’s marketable securities and other investments.

X

- Definition

The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2021-01-01
-Paragraph 31
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2021-01-01
-Paragraph 7
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 7
-IssueDate 2021-01-01
-Paragraph 35K
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard
-URIDate 2021-03-24

+ Details

Name:	ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfFinancialInstrumentsAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration